Centessa Pharmaceuticals plc - ADR CNTA

NAS: CNTA | ISIN: US1523091007   17/05/2024
8,870 USD (-0,89%)
(-0,89%)   17/05/2024

13 mei 2024 · Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 · Persbericht

24 april 2024 · Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares · Persbericht

23 april 2024 · Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares · Persbericht

22 april 2024 · Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 · Persbericht

28 maart 2024 · Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 · Persbericht

10 december 2023 · Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia · Persbericht

13 november 2023 · Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023 · Persbericht

25 oktober 2023 · Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders · Persbericht

14 augustus 2023 · Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023 · Persbericht

10 juli 2023 · Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors · Persbericht

24 mei 2023 · Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences · Persbericht

22 mei 2023 · Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B · Persbericht

12 mei 2023 · Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023 · Persbericht

30 maart 2023 · Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022 · Persbericht

27 maart 2023 · Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences · Persbericht

23 maart 2023 · Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director · Persbericht

1 maart 2023 · Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines · Persbericht

6 februari 2023 · Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) · Persbericht

2 februari 2023 · Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference · Persbericht

26 januari 2023 · Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors · Persbericht

Mijn selecties